Alembic Pharmaceuticals Limited has announced the re-appointment of Pranav Amin as Managing Director for a five-year term starting April 1, 2026, with the post not liable to retirement by rotation. The decision, approved by shareholders at the company’s 15th Annual General Meeting held on August 5, 2025, solidifies continuity at the helm for a new five-year horizon.
Pranav Amin currently heads the company’s International Business and is credited with steering Alembic’s push into global markets. In the attached notes, the leadership profile highlights a clear focus on innovation, research and development, and high-quality manufacturing, which the company says have contributed to sustained growth in revenue and profitability under his leadership.
The announcement also underscores a close-knit leadership lineage within Alembic, noting that Chirayu Amin—the Chairman of the company—is the father of Pranav Amin and Shaunak Amin, who also serves as a Managing Director. Together, the trio anchors a governance and strategy framework that the firm describes as geared toward international expansion and continued emphasis on quality and innovation.
This development marks a moment of strategic continuity for Alembic as it eyes deeper penetration of international markets and ongoing product development, supported by an executive leadership team that blends experience with a long-standing family-led governance approach.